Valneva is giving up on a contract worth more than 30 million euros. The French laboratory indicates on August 18 that the American Department of Defense will not exercise its option for the purchase of doses of vaccine against Japanese encephalitis, considering that its supplies are sufficient to meet its needs.
According to Valneva, the decision not to exercise Ixiaro’s second supply option has no impact on its financial forecasts for 2022. The group specifies that this option had a nominal value of 36 million dollars for 250,000 doses.
The ‘DoD’ (US Department of Defense-Editor’s note) considers that its existing supply levels of Ixiaro are sufficient to meet its current needs”, explains the company in a press release.
Valneva anticipates for 2022 a turnover of between 340 and 360 million euros.
With Reuters (Matthieu Protard)
Source: UsineNouvelle – Actualités A la une by www.usinenouvelle.com.
*The article has been translated based on the content of UsineNouvelle – Actualités A la une by www.usinenouvelle.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!